



CanVeer
Biopharma

**Innovative Science to Safeguard Every
Newborn's First Breath.**

Corporate Overview

January 2026

Forward Looking Statement



This document and any attachments are intended for information purposes only and should not be construed as an offer or solicitation for the sale of securities. Statements in this presentation include forward-looking statements within the meaning of certain securities laws. These forward-looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words “expected to” “illustrate” “has the potential to” “will be”, “evaluating” “plans” “can be” “planning” “to predict” “potential” “may” “should” and words and expressions of similar import, are intended to identify forward-looking statements. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not put undue reliance on these statement or the scientific data presented as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. We do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.



SIGNIFICANT OPPORTUNITY

- In North America approximately **180,000** preterm neonates every year require assisted ventilation at birth and are at risk to develop BPD, leading to **TAM of approximately 8B**

NO DIRECT OR INDIRECT COMPETITION

- Despite decades of neonatal research, **there is ZERO approved pharmaceutical therapy exist (or in-development)** to prevent or treat Bronchopulmonary dysplasia (BPD)

ACCELERATED DEVELOPMENT POTENTIAL

- **AlveoShield™** is potentially eligible for **3 regulatory designations** including: **ORPHAN DRUG** (market exclusivity); **PEDIATRIC RARE DISEASE** (fast priority review); **BREAKTHROUGH THERAPY** (rolling FDA submission)
- Pediatric disease clinical trials require reduced number of patients
- Phas2/3 clinical trial primary endpoints are designed at **36 weeks** (compared to several years for adult clinical trials)


SECURED IP & EXPERIENCED LEADERSHIP

- Provisional Patent filed in 2025 (**IP protected till 2045**). All IP rights are solely owned by CanVeer Biopharma Inc. (**no royalty provisions**)
- The Leadership team brings 35+ years of combined experience leading Healthcare Innovation & commercialization

The Need: Bronchopulmonary Dysplasia (BPD) - A Newborn Clinical Crisis




- ❑ **400,000+** infants annually in North America (US & Canada) are born preterm
- ❑ **Approximately 40% will require assisted ventilation at birth and are at risk to develop BPD** - lifelong lung damage, \$500K+ lifetime healthcare costs
- ❑ **Current standard of care:** Supportive oxygen & surfactants only, no disease-modifying treatment
- ❑ **\$8B+ North American market** with no approved direct or indirect therapies







- ❑ **Novel therapeutic** for BPD prevention in ventilated preterm infants
- ❑ **Validated compound** with established human safety profile
- ❑ **Mechanism:** Targets underlying disease pathology (**proprietary - patent pending**)
- ❑ **Differentiated approach:** Prevents lung damage rather than managing symptoms, with potential to reverse BPD

Milestones Achieved to Date



Increased Target Expression in BPD Patients - Characterized biological pathway




- ❑ Lung tissues from 47 preterm infants analyzed
- ❑ **3.2x higher expression** of key therapeutic target in BPD vs control infants ($p < 0.01$)
- ❑ Target localized to distal lung epithelium - site of BPD pathology



Human Lung Epithelial Cells (A549)

- ❑ Hyperoxia (85% O₂) → **rapid apoptotic intermediates accumulation** within 6 hours
- ❑ **Dose-dependent apoptosis reduction** with **AlveoShield** treatment
- ❑ **Mechanistic validation:** Treatment prevents apoptosis cascade

A




Compelling Preclinical Evidence - *in vivo* Efficacy (Neonate Rat Model)




Hyperoxia-Induced Lung Injury Model

- ❑ 24-hour exposure: **47% reduction in apoptotic intermediates** with AlveoShield treatment
- ❑ 7-day exposure: **68% reduction in apoptosis** (TUNEL assay, $p < 0.05$)
- ❑ **Structural protection:** Preserved alveolar architecture


Air Vehicle
(Day7)




Hyperoxia vehicle
(Day7)



Hyperoxia + AlveoShield
(Day7)



AlveoShield - Path to the Clinic & Development Strategy



- ✓ **140,000-170,000 eligible infants annually** in well-developed markets across North America (USA & Canada)
- ✓ **Market standard orphan drug pricing: \$50,000-\$150,000 per course**
- ✓ **NICU-focused distribution** through hospital specialty pharmacies
- ✓ **Partnership approach** with established neonatal pharma company





5-Year Projections:

- ✓ **Year 3:** Interim endpoint Results → \$150-300M valuation
- ✓ **Year 4:** Phase 2/3 completion → \$500M-1B valuation
- ✓ **Peak Sales:** \$1.5B+ (40% market penetration)

Exit Strategy:

- ✓ **Acquisition target** for companies with neonatal portfolios (AbbVie, Merck, Roche)
- ✓ **Partnership** with specialty pharma (Mallinckrodt, Chiesi)
- ✓ **IPO** if platform expansion opportunities emerge



Seasoned Leadership Team & Advisory Board



Sherif Louis, PhD, MBA(c)
CEO

- ✓ 15+ years biotech Executive leadership
- ✓ Successfully commercialized academic healthcare IP
- ✓ Multiple rounds of multimillion dollars capital raises
- ✓ Deep regulatory experience (ISO, CAP, CLIA certifications)



Dr. Behzad Yeganeh, PhD
CSO & Inventor

- ✓ 20+ years of cutting-edge health research
- ✓ Leading neonatal lung injury researcher
- ✓ 45+ publications in high-impact journals
- ✓ Strong KOL network in neonatology
- ✓ Inventor on several patents

Advisory Board

Dr. Robert Jankov, MD, PhD

Distinguished Physician & Scientist specialized in neonatal pulmonary vascular disease.

Dr. Martin Post, PhD

A veteran R&D with proven long-term expertise in lung development injury and repair.

Ali Hamraghani, PharmD, MSc

Therapeutics formulation expert with extensive experience in pharmaceuticals R&D.

Dr. Azadeh Yeganeh, PhD

Regulatory expert specialized in regulatory review of preclinical and clinical data, including regulatory risk assessments.



CanVeer
Biopharma

**Innovative Science to Safeguard Every
Newborn's First Breath.**

Contact:

Sherif Louis
CEO

Address:

3650 Kaneff Cres. Mississauga
ON, Canada L5A 4A1

Email: info@canveer.com

Tel: +1 (647) 293-6555